Codexis, Inc. logo — Transforming Therapeutic Manufacturing

Codexis, Inc.

Transforming Therapeutic Manufacturing

Founded 2002 United States Redwood City, United States 240 employees IPO Total: $202.00M Biotechnology, Sustainability

General Information

Company Name Codexis, Inc.
Founded Year 2002
Location United States Redwood City, United States
Employees 240
Industries Biotechnology, Sustainability
Funding Stage IPO
Business Model B2B, SaaS, API
Revenue Model Service Fee, Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Codexis, Inc.. To contact Codexis, Inc., visit codexis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Codexis, Inc. compare?

A PDF of Codexis, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Codexis, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Codexis, Inc.

Codexis, Inc., founded in 2002, is a U.S.-based biotechnology company revolutionizing therapeutic manufacturing with its innovative platforms. As stated in its slogan, “Transforming Therapeutic Manufacturing,” the company leverages proprietary technology to outperform traditional methods, opening new possibilities for therapeutic development.

Positioned at the intersection of Biotechnology and Sustainability, Codexis has established itself as not just a solutions provider but a long-term partner in the therapeutic field. The company's consistent track record is underscored by its commitment to advancing beyond conventional boundaries and driving progress in complex therapeutic manufacturing.

In terms of financial traction, the company's recent $40.00M Post Ipo Debt investment on 01 February 2024 from Innovatus Capital Partners signals robust investor confidence in its business model. This capital injection is poised to further its technology and market leadership.

Business keywords: Therapeutic Manufacturing, Biocatalysis, Enzyme Engineering, Directed Evolution, Pharmaceutical Manufacturing, Chemical Production, Enzyme Optimization, API Manufacturing, RNA Manufacturing, Oligo Synthesis, Pharma Biocatalysis, Enzyme Development, siRNA Manufacturing, CodeEvolver Technology

Services & Products

RNA Manufacturing Services
Pharma Biocatalysis
Enzyme Screening Kits and Panels
Tailored Enzymes
R&D Enzyme Services
Transformational Technology Platforms

Target Customers

Pharmaceutical Companies Biotechnology Firms Molecular Biology Researchers Diagnostic Application Developers Therapeutic Manufacturing Entities

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt $40.00M 1
Innovatus Capital Partners
01 Feb 2024
Post-IPO Equity $75.00M -
01 Dec 2020
Post-IPO Equity $50.00M 2
Casdin Capital, Vivo Capital
01 Jun 2019
IPO Undisclosed -
01 Apr 2010
Series D $37.00M 5
EDBI, Chevron Technology Ventures +3
01 Aug 2006

Codexis, Inc. Alternatives & Competitors

Codexis, Inc. vs
Rubi Laboratories
Rubi Laboratories United States

We turn carbon emissions into carbon-negative textiles.

Grant
29 employees
Biotechnology, Manufacturing

FAQ About Codexis, Inc.

Transforming Therapeutic Manufacturing
Codexis, Inc. was founded in 2002.
Codexis, Inc. is headquartered in Redwood City, United States.
Codexis, Inc. operates in Biotechnology and Sustainability. Its work centres on Therapeutic Manufacturing, Biocatalysis, Enzyme Engineering and Directed Evolution. Its customers include Pharmaceutical Companies, Biotechnology Firms and Molecular Biology Researchers.
Codexis, Inc. has a B2B, SaaS and API business model. Its revenue comes from Service Fee, Licensing and Product Sales.
Codexis, Inc. has approximately 240 employees.
Codexis, Inc. has completed 5 funding rounds, raising a total of $202.00M. The latest funding stage is IPO.
Codexis, Inc. offers: RNA Manufacturing Services, Pharma Biocatalysis, Enzyme Screening Kits and Panels, Tailored Enzymes, R&D Enzyme Services, Transformational Technology Platforms.
Top alternatives and competitors to Codexis, Inc. include Rubi Laboratories. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Codexis, Inc. and Rubi Laboratories are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Codexis, Inc., https://bouncewatch.com/company/codexis-inc, updated 2 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes